Skip to main content

Table 3 Adjusted RRs for the association between pregnancy-related factors and the subtypes of invasive breast cancer

From: Pregnancy-related factors and the risk of breast carcinoma in situand invasive breast cancer among postmenopausal women in the California Teachers Study cohort

 

ER+

ER-

ER+/PR+

ER-/PR-

 

Cases No.

Adjusted RR (95% CI)

Cases No.

Adjusted RR (95% CI)

Cases No.

Adjusted RR (95% CI)

Cases No.

Adjusted RR (95% CI)

All women

        

Ever pregnant

        

   No

382

Reference

56

Reference

318

Reference

50

Reference

   Yes

1,722

0.87 (0.78 to 0.97)

283

0.99 (0.74 to 1.31)

1,333

0.81 (0.71 to 0.91)

267

1.04 (0.77 to 1.41)

P for homogeneitya

0.42

   

0.12

  

Number of full-term pregnancyb

        

   1

272

0.93 (0.80 to 1.09)

33

0.78 (0.51 to 1.20)

218

0.90 (0.75 to 1.06)

32

0.85 (0.55 to 1.33)

   2

640

0.88 (0.77 to 1.00)

121

1.15 (0.84 to 1.58)

485

0.80 (0.69 to 0.92)

111

1.19 (0.85 to 1.66)

   3

443

0.85 (0.74 to 0.98)

66

0.88 (0.62 to 1.26)

352

0.82 (0.70 to 0.95)

66

0.99 (0.68 to 1.43)

   ≥ 4

267

0.76 (0.65 to 0.89)

45

0.90 (0.61 to 1.34)

206

0.71 (0.59 to 0.85)

40

0.90 (0.59 to 1.37)

   P trend

 

0.0004

 

0.72

 

< 0.0001

 

0.85

P for homogeneitya

0.33

   

0.17

  

Ever pregnant, incomplete pregnancies only or outcome of pregnancies unknown

100

 

18

 

72

 

18

 

Parous women only c, d

        

Number of full-term pregnancies

        

   1

272

Reference

33

Reference

218

Reference

32

Reference

   2

638

0.96 (0.83 to 1.11)

121

1.51 (1.01 to 2.25)

484

0.91 (0.77 to 1.08)

111

1.39 (0.92 to 2.10)

   3

443

0.95 (0.80 to 1.12)

65

1.18 (0.75 to 1.86)

352

0.95 (0.79 to 1.15)

65

1.17 (0.74 to 1.85)

   ≥ 4

267

0.85 (0.70 to 1.04)

45

1.24 (0.75 to 2.07)

206

0.84 (0.68 to 1.05)

40

1.08 (0.64 to 1.83)

   P trend

 

0.13

 

0.99

 

0.25

 

0.74

P for homogeneitya

 

0.57

   

0.87

  

Age at first full-term pregnancy, years

        

   < 21

152

Reference

22

Reference

120

Reference

21

Reference

   21 to 24

527

1.04 (0.87 to 1.25)

97

1.37 (0.86 to 2.18)

413

1.04 (0.85 to 1.28)

90

1.31 (0.81 to 2.12)

   25 to 29

660

1.21 (1.01 to 1.45)

98

1.31 (0.82 to 2.10)

501

1.18 (0.97 to 1.45)

93

1.28 (0.79 to 2.07)

   30 to 34

204

1.17 (0.94 to 1.46)

39

1.71 (0.99 to 2.95)

166

1.23 (0.96 to 1.57)

37

1.66 (0.95 to 2.90)

   ≥ 35

77

1.37 (1.02 to 1.83)

8

1.21 (0.52 to 2.81)

60

1.36 (0.98 to 1.89)

7

1.07 (0.44 to 2.60)

   P trend

 

0.004

 

0.23

 

0.009

 

0.30

   P for homogeneitya

 

0.96

   

0.92

  

Duration of breastfeeding, months

        

   Never

499

Reference

80

Reference

379

Reference

75

Reference

   < 6

433

0.98 (0.86 to 1.11)

68

0.97 (0.70 to 1.34)

346

1.03 (0.89 to 1.19)

63

0.96 (0.69 to 1.34)

   6 to 11

296

1.06 (0.92 to 1.23)

52

1.15 (0.81 to 1.63)

229

1.08 (0.91 to 1.27)

50

1.16 (0.81 to 1.67)

   12 to 23

259

1.04 (0.89 to 1.21)

42

1.02 (0.69 to 1.50)

205

1.08 (0.90 to 1.29)

39

1.02 (0.69 to 1.52)

   ≥ 24

133

1.02 (0.83 to 1.25)

22

1.00 (0.61 to 1.66)

101

1.00 (0.80 to 1.27)

21

1.06 (0.64 to 1.78)

   P trend

 

0.52

 

0.78

 

0.54

 

0.65

   P for homogeneitya

 

0.98

   

0.88

  
  1. RRs are from multivariable Cox proportional hazards regression models using age (in days) as the time metric and stratified by age (in years) with the adjustment for race, family history of breast cancer in a first degree relative, age at menarche, HT use, body mass index. aHomogeneity in risk estimates between subtypes of invasive breast cancer. bCompared with nulligravid women. cAdditionally, number of full-term pregnancies, age at first full-term pregnancy, and duration of breastfeeding mutually adjusted among parous women. dAdditionally excluded parous women who were missing information on breastfeeding or age at first full-term pregnancy. Abbreviations: RR, relative risk; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HT, hormone therapy.